IDEXX Laboratories (NASDAQ:IDXX) Stock Unloaded Rep. April McClain Delaney

Key Points

• Representative April McClain Delaney sold shares of IDEXX Laboratories, Inc. worth between $1,001 and $15,000 on August 7th, according to a filing disclosed on September 2nd.
• IDEXX Laboratories reported earnings of $3.63 per share, exceeding analysts' expectations of $3.28, with a quarterly revenue of $1.11 billion, marking a year-over-year increase of 10.6%.
• Insider activity at IDEXX included notable stock sales by Director M Anne Szostak and EVP Sharon E. Underberg, with recent trades amounting to over $34 million in total insider sales.

Representative April McClain Delaney (D-Maryland) recently sold shares of IDEXX Laboratories, Inc. NASDAQ: IDXX. In a filing disclosed on September 02nd, the Representative disclosed that they had sold between $1,001 and $15,000 in IDEXX Laboratories stock on August 7th.

Representative April McClain Delaney also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of BJ's Wholesale Club NYSE: BJ on 8/25/2025.
• Purchased $15,001 - $50,000 in shares of Markel Group NYSE: MKL on 8/21/2025.
• Sold $15,001 - $50,000 in shares of Dayforce NYSE: DAY on 8/19/2025.
• Sold $1,001 - $15,000 in shares of Viking NYSE: VIK on 8/13/2025.
• Sold $15,001 - $50,000 in shares of Core & Main NYSE: CNM on 8/11/2025.
• Purchased $1,001 - $15,000 in shares of Jones Lang LaSalle NYSE: JLL on 8/7/2025.
• Purchased $1,001 - $15,000 in shares of Markel Group NYSE: MKL on 8/7/2025.
• Sold $1,001 - $15,000 in shares of Clean Harbors NYSE: CLH on 8/7/2025.
• Purchased $15,001 - $50,000 in shares of Morningstar NASDAQ: MORN on 8/2/2025.
• Sold $1,001 - $15,000 in shares of Bio-Techne NASDAQ: TECH on 8/1/2025.

IDEXX Laboratories Trading Up 0.4%

Shares of NASDAQ:IDXX traded up $2.55 during trading on Friday, hitting $642.99. 370,390 shares of the company's stock were exchanged, compared to its average volume of 413,114. IDEXX Laboratories, Inc. has a 1-year low of $356.14 and a 1-year high of $688.12. The firm has a 50-day moving average price of $593.22 and a two-hundred day moving average price of $507.11. The company has a current ratio of 1.11, a quick ratio of 0.79 and a debt-to-equity ratio of 0.31. The firm has a market cap of $51.44 billion, a P/E ratio of 53.54, a PEG ratio of 4.16 and a beta of 1.56.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its quarterly earnings results on Monday, August 4th. The company reported $3.63 EPS for the quarter, topping the consensus estimate of $3.28 by $0.35. IDEXX Laboratories had a net margin of 24.41% and a return on equity of 64.42%. The company had revenue of $1.11 billion during the quarter, compared to analysts' expectations of $1.06 billion. During the same quarter in the previous year, the company earned $2.44 EPS. IDEXX Laboratories's revenue was up 10.6% on a year-over-year basis. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. Equities analysts predict that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

Wall Street Analyst Weigh In

IDXX has been the subject of several analyst reports. Stifel Nicolaus set a $640.00 price target on shares of IDEXX Laboratories in a research report on Monday, August 4th. Jefferies Financial Group assumed coverage on shares of IDEXX Laboratories in a report on Tuesday, July 1st. They set a "buy" rating and a $625.00 price objective for the company. Piper Sandler restated a "neutral" rating and set a $700.00 price objective (up previously from $510.00) on shares of IDEXX Laboratories in a report on Monday, August 11th. JPMorgan Chase & Co. boosted their price objective on shares of IDEXX Laboratories from $550.00 to $675.00 and gave the company an "overweight" rating in a report on Monday, August 4th. Finally, BTIG Research boosted their price objective on shares of IDEXX Laboratories from $545.00 to $785.00 and gave the company a "buy" rating in a report on Tuesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $649.44.

Institutional Investors Weigh In On IDEXX Laboratories

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Mercer Global Advisors Inc. ADV boosted its position in IDEXX Laboratories by 7.4% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 4,667 shares of the company's stock worth $1,929,000 after buying an additional 321 shares during the period. Aptus Capital Advisors LLC boosted its position in IDEXX Laboratories by 1,483.8% during the 4th quarter. Aptus Capital Advisors LLC now owns 9,962 shares of the company's stock worth $4,119,000 after buying an additional 9,333 shares during the period. Algert Global LLC boosted its position in IDEXX Laboratories by 10.3% during the 4th quarter. Algert Global LLC now owns 10,113 shares of the company's stock worth $4,181,000 after buying an additional 942 shares during the period. BNP Paribas Financial Markets boosted its position in IDEXX Laboratories by 221.3% during the 4th quarter. BNP Paribas Financial Markets now owns 441,319 shares of the company's stock worth $182,459,000 after buying an additional 303,966 shares during the period. Finally, Benjamin Edwards Inc. boosted its position in IDEXX Laboratories by 77.5% during the 4th quarter. Benjamin Edwards Inc. now owns 3,337 shares of the company's stock worth $1,380,000 after buying an additional 1,457 shares during the period. 87.84% of the stock is owned by institutional investors.

Insider Buying and Selling at IDEXX Laboratories

In other news, EVP Michael G. Erickson sold 406 shares of the business's stock in a transaction that occurred on Tuesday, August 12th. The shares were sold at an average price of $649.96, for a total value of $263,883.76. Following the transaction, the executive vice president owned 11,287 shares in the company, valued at approximately $7,336,098.52. The trade was a 3.47% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Nimrata Hunt sold 1,200 shares of the business's stock in a transaction that occurred on Monday, August 11th. The stock was sold at an average price of $656.53, for a total transaction of $787,836.00. Following the completion of the transaction, the executive vice president owned 16,807 shares in the company, valued at $11,034,299.71. This trade represents a 6.66% decrease in their position. The disclosure for this sale can be found here. Insiders sold 54,057 shares of company stock worth $34,293,468 over the last quarter. Insiders own 0.98% of the company's stock.

About Representative McClain Delaney

April McClain-Delaney (Democratic Party) is a member of the U.S. House, representing Maryland's 6th Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027. McClain-Delaney (Democratic Party) is running for re-election to the U.S. House to represent Maryland's 6th Congressional District. She declared candidacy for the 2026 election. April McClain-Delaney grew up in Buhl, Idaho, where her father was a potato farmer. She obtained her bachelor's degree in communications from Northwestern University in 1986 and her law degree from Georgetown Law Center in 1989. McClain-Delaney worked in communications law, first with the satellite firm Orion Network Systems and later as the Washington director for Common Sense Media, a nonprofit focused on technology and children. In 2022, McClain-Delaney joined the U.S. Department of Commerce under President Joe Biden (D) as deputy assistant secretary for communications and information. McClain-Delaney served on the board of the Georgetown University Law Center, the International Center for Research on Women, and the Northwestern University School of Communications.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.